Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06751602 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Belumosudil for Abrogation of Interstitial Fibrosis and Tubular Atrophy Following Kidney Transplantation

StatusEnrolling by Invitation
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv5
  2. Trial status: Not Yet Recruiting to Enrolling by Invitation Start date changed from estimate of Apr 15, 2025 to Sep 11, 2025 · Site contact updatedv4 Show 2 more changesShow less
    • Start date changed from estimate of Apr 15, 2025 to Sep 11, 2025
    • Site contact updated
  3. Site contact updatedv3
  4. Start date: Jan 15, 2025 to Apr 15, 2025 Primary completion date: Sep 30, 2027 to Dec 2027 · Study description expanded, about 3 wordsv2 Show 2 more changesShow less
    • Primary completion date: Sep 30, 2027 to Dec 2027
    • Study description expanded, about 3 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blind, placebo-controlled trial in de novo kidney transplant patients to determine if the addition of belumosudil (brand name- REZUROCK®) on the background of standard immunosuppression will prevent fibrosis in the kidney transplant. Interstitial expansion is the precursor of interstitial fibrosis and graft loss. The hypothesis underlying the study is that abgrogating the fibrogenic effects of the RhoA pathway with belumosudil will reduce structural damage in transplanted kidneys and possible subsequent transplant failure.
Trial Details
NCT Number NCT06751602
Lead Sponsor The Methodist Hospital Research Institute
Conditions Rejection Chronic Renal
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov